YU56995A - Soli derivata indola - Google Patents

Soli derivata indola

Info

Publication number
YU56995A
YU56995A YU56995A YU56995A YU56995A YU 56995 A YU56995 A YU 56995A YU 56995 A YU56995 A YU 56995A YU 56995 A YU56995 A YU 56995A YU 56995 A YU56995 A YU 56995A
Authority
YU
Yugoslavia
Prior art keywords
indola
derived
alpha
compounds
formula
Prior art date
Application number
YU56995A
Other languages
English (en)
Other versions
YU49287B (sh
Inventor
Harding
Macrae
Ogilvie
Original Assignee
Pfizer Research And Development Company N.V./S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10760474&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU56995(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Research And Development Company N.V./S.A. filed Critical Pfizer Research And Development Company N.V./S.A.
Publication of YU56995A publication Critical patent/YU56995A/sh
Publication of YU49287B publication Critical patent/YU49287B/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Reciprocating, Oscillating Or Vibrating Motors (AREA)

Abstract

Pronalazak se odnosi na alfa-polimorfne oblike jedinjenja formule (I): na proces njegove pripreme, na intermedijerni beta-polimorfni oblik i na farmaceutske kompozicije i njegovu terapeutsku upotrebu.
YU56995A 1994-08-27 1995-08-25 Soli derivata indola YU49287B (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9417310A GB9417310D0 (en) 1994-08-27 1994-08-27 Therapeutic agents

Publications (2)

Publication Number Publication Date
YU56995A true YU56995A (sh) 1998-07-10
YU49287B YU49287B (sh) 2005-03-15

Family

ID=10760474

Family Applications (1)

Application Number Title Priority Date Filing Date
YU56995A YU49287B (sh) 1994-08-27 1995-08-25 Soli derivata indola

Country Status (45)

Country Link
US (2) US6110940A (sh)
EP (1) EP0776323B1 (sh)
JP (1) JP2904588B2 (sh)
KR (1) KR100228952B1 (sh)
CN (1) CN1066727C (sh)
AP (1) AP576A (sh)
AT (1) ATE163182T1 (sh)
AU (1) AU691005B2 (sh)
BG (1) BG61840B1 (sh)
BR (1) BRPI9503812B1 (sh)
CA (1) CA2198599C (sh)
CO (1) CO4410334A1 (sh)
CZ (1) CZ287693B6 (sh)
DE (1) DE69501620T2 (sh)
DK (1) DK0776323T3 (sh)
DZ (1) DZ1923A1 (sh)
EG (1) EG23822A (sh)
ES (1) ES2112650T3 (sh)
FI (1) FI113768B (sh)
GB (1) GB9417310D0 (sh)
GR (1) GR3026475T3 (sh)
HR (1) HRP950460B1 (sh)
HU (1) HU227822B1 (sh)
IL (1) IL115013A (sh)
IS (1) IS1850B (sh)
LV (1) LV11800B (sh)
MA (1) MA23650A1 (sh)
MX (1) MX9701538A (sh)
MY (1) MY113733A (sh)
NO (1) NO311297B1 (sh)
NZ (1) NZ288210A (sh)
OA (1) OA10600A (sh)
PE (1) PE41596A1 (sh)
PL (1) PL180867B1 (sh)
RO (1) RO116400B1 (sh)
RU (1) RU2159241C2 (sh)
SA (1) SA95160156B1 (sh)
SI (1) SI9520091B (sh)
SK (1) SK282922B6 (sh)
TN (1) TNSN95092A1 (sh)
TR (1) TR199501061A2 (sh)
UA (1) UA45980C2 (sh)
WO (1) WO1996006842A1 (sh)
YU (1) YU49287B (sh)
ZA (1) ZA957142B (sh)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9420529D0 (en) 1994-10-12 1994-11-30 Pfizer Ltd Indoles
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
CA2292673C (en) * 1997-07-03 2003-04-22 Pfizer Inc. Pharmaceutical compositions containing eletriptan hemisulphate
GB9714081D0 (en) * 1997-07-03 1997-09-10 Pfizer Ltd Pharmaceutical compositions
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
GB9825988D0 (en) * 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
GB9922963D0 (en) * 1999-09-28 1999-12-01 Pfizer Ltd Polymorphic salt
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
GB9923314D0 (en) 1999-10-01 1999-12-08 Pfizer Ltd Acylation process
JP2001172178A (ja) * 1999-10-25 2001-06-26 Pfizer Prod Inc 偏頭痛治療用のｎｋ−１レセプターアンタゴニスト及びエレトリプタン
US7108970B2 (en) 2000-01-07 2006-09-19 Transform Pharmaceuticals, Inc. Rapid identification of conditions, compounds, or compositions that inhibit, prevent, induce, modify, or reverse transitions of physical state
US20040252299A9 (en) 2000-01-07 2004-12-16 Lemmo Anthony V. Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions
GB0008563D0 (en) 2000-04-07 2000-05-24 Cambridge Discovery Chemistry Investigating different physical and/or chemical forms of materials
GB0018968D0 (en) * 2000-08-02 2000-09-20 Pfizer Ltd Particulate composition
US20030166704A1 (en) * 2000-12-20 2003-09-04 Pfizer Inc. New process
US6579898B2 (en) 2001-03-01 2003-06-17 Pfizer Inc. Compositions having improved bioavailability
JP2006522790A (ja) 2003-04-11 2006-10-05 ファイザー・インク エレトリプタンと重炭酸ナトリウムを含む医薬組み合わせ物
US7132549B2 (en) 2003-05-30 2006-11-07 Pfizer Inc. Process
GB0312478D0 (en) * 2003-05-30 2003-07-09 Pfizer Ltd Improved process
GB0317229D0 (en) * 2003-07-23 2003-08-27 Pfizer Ltd Improved process
US6927296B2 (en) 2003-07-23 2005-08-09 Pfizer Inc. Process
EP2502621A1 (en) * 2005-06-27 2012-09-26 Valeant International (Barbados) SRL Crystalline forms of bupropion HBr
BRPI0715579A2 (pt) * 2006-10-19 2015-05-26 Auspex Pharmaceuticals Inc "composto, composição farmacêutica e uso de um composto"
US20080139510A1 (en) * 2006-12-07 2008-06-12 Abe Rose Treatment of migraine headaches with sublingual amino acids
EP1956018A1 (de) * 2007-02-06 2008-08-13 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Herstellung eines Benzimidazolderivats
EP2046777A2 (en) * 2007-05-01 2009-04-15 Plus Chemicals B.V. Amorphous eletriptan hydrobromide and process for preparing it and other forms of eletriptan hydrobromide
US20080319205A1 (en) * 2007-05-29 2008-12-25 Roman Bednar Process for preparing 5-bromo-3-[(R)-1-methyl-pyrrolidin-2-ylmethyl]-1H-indole
US20100285075A1 (en) * 2007-12-17 2010-11-11 Actavis Group Ptc Ehf Novel Hemioxalate Salt of Eletriptan
US20090299077A1 (en) * 2008-05-22 2009-12-03 Vinod Kumar Kansal Salts of (R)-5-(2phenylsulphonylethenyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole, 5-bromo-3-[(R)-1-methyl-pyrrolidin-2-ylmethyl]-1H-indole and of eletriptan
US8349900B2 (en) * 2008-08-07 2013-01-08 Valeant International Bermuda Bupropion hydrobromide polymorphs
US20120027816A1 (en) * 2009-02-25 2012-02-02 Actavis Group Ptc Ehf Highly pure eletriptan or a pharmaceutically acceptable salt thereof substantially free of eletriptan n-oxide impurity
WO2010116386A2 (en) * 2009-04-08 2010-10-14 Biophore India Pharmaceuticals Pvt. Ltd. Novel polymorph of eletriptan hydrobromide and process for the preparation thereof
IT1393700B1 (it) 2009-04-22 2012-05-08 F S I Fabbrica Italiana Sint Sintesi di 3-{[(2r)-1-metilpirrolidin-2-il]metil}-5-[2-(fenilsulfonil)etil]-1h-indolo
WO2011004391A2 (en) * 2009-06-25 2011-01-13 Matrix Laboratories Ltd An improved process for the preparation of eletriptan and its salt thereof
WO2011089614A1 (en) * 2010-01-19 2011-07-28 Sms Pharmaceuticals Limited PROCESS FOR PREPARING ELETRIPTAN HYDROBROMIDE HAVING α-FORM
WO2014063752A1 (en) 2012-10-26 2014-05-01 Synthon Bv Process for making crystalline form alpha of eletriptan hydrobromide
JP2019502761A (ja) 2016-01-21 2019-01-31 ラボラトリオス レヴィ エセエレ （（ｒ）−３−［（−１−メチルピロリジン−２−イル）メチル］−５−（２−フェニルスルホニルエチル）−１ｈ−インドールを作製する方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2773875A (en) * 1952-03-28 1956-12-11 Hoffmann La Roche Indole derivatives and method for producing same
GB886684A (en) * 1957-09-17 1962-01-10 Upjohn Co Improvements in or relating to heterocyclic compounds and the manufacture thereof
GB851780A (en) * 1958-02-25 1960-10-19 Rhone Poulenc Sa New indole derivatives
US3037031A (en) * 1959-08-04 1962-05-29 Warner Lambert Pharmaceutical Derivatives of 3-(2-aminoalkyl)-5-indolol and process therefor
GB893707A (en) * 1960-03-01 1962-04-11 Roche Products Ltd Novel tryptamine derivatives and a process for the manufacture thereof
GB966562A (en) * 1961-04-06 1964-08-12 Parke Davis & Co Amine compounds and means of producing the same
US4092315A (en) * 1976-03-01 1978-05-30 Pfizer Inc. Novel crystalline forms of prazosin hydrochloride
ZA795239B (en) * 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
ZW19381A1 (en) * 1980-08-12 1983-03-09 Glaxo Group Ltd Heterocyclic compounds
US4803218A (en) * 1982-09-29 1989-02-07 Mcneilab, Inc. 3-aminoalkyl-1H-indole-5-urea and amide derivatives
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
DK158590D0 (da) * 1990-07-02 1990-07-02 Lundbeck & Co As H Indolderivater
US5559246A (en) * 1990-10-15 1996-09-24 Pfizer Inc. Indole derivatives
BR9106978A (pt) * 1990-10-15 1993-09-28 Pfizer Derivados de indol
US5578612A (en) * 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
US5559129A (en) * 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5208248A (en) * 1991-01-11 1993-05-04 Merck Sharpe & Dohme, Ltd. Indazole-substituted five-membered heteroaromatic compounds
CZ283018B6 (cs) * 1991-02-01 1997-12-17 Merck Sharp And Dohme Limited Deriváty imidazolu, triazolu a tetrazolu a farmaceutické přípravky na jejich bázi
CZ281874B6 (cs) * 1991-11-25 1997-03-12 Pfizer Inc. Indolové deriváty, způsob jejich přípravy, meziprodukty tohoto postupu, farmaceutické prostředky obsahující tyto indolové deriváty a použití.
GB9201038D0 (en) * 1992-01-16 1992-03-11 Glaxo Group Ltd Chemical compounds
US5409941A (en) * 1992-02-03 1995-04-25 Pfizer Inc. 5-heteroyl indole derivatives
TW288010B (sh) * 1992-03-05 1996-10-11 Pfizer
CA2133413C (en) * 1992-04-07 2001-04-10 John Eugene Macor Indole derivatives as 5-ht1 antagonists
GB9207930D0 (en) * 1992-04-10 1992-05-27 Pfizer Ltd Indoles
US5498626A (en) * 1992-04-10 1996-03-12 Pfizer Inc. Acylaminoindole derivatives as 5-ht1 agonists
GB9208161D0 (en) * 1992-04-14 1992-05-27 Pfizer Ltd Indoles
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
FR2701026B1 (fr) * 1993-02-02 1995-03-31 Adir Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
CA2157397C (en) * 1993-04-22 1999-07-06 Martin James Wythes Indole derivatives as 5-ht1-like agonists for use in migraine
AP486A (en) * 1993-04-27 1996-04-16 Pfizer Indole derivatives.
ATE170836T1 (de) * 1993-08-31 1998-09-15 Pfizer 5-arylindolderivate

Also Published As

Publication number Publication date
HUT77310A (hu) 1998-03-30
JPH09512283A (ja) 1997-12-09
PE41596A1 (es) 1996-10-12
TNSN95092A1 (fr) 1996-02-06
SI9520091A (sl) 1998-02-28
DE69501620D1 (de) 1998-03-19
HRP950460A2 (en) 1997-08-31
AU691005B2 (en) 1998-05-07
PL180867B1 (pl) 2001-04-30
AP576A (en) 1997-03-20
FI970800A (fi) 1997-02-26
AU2735295A (en) 1996-03-22
NO970861D0 (no) 1997-02-26
BRPI9503812B1 (pt) 2017-04-18
FI113768B (fi) 2004-06-15
CN1155886A (zh) 1997-07-30
IL115013A (en) 2000-11-21
GB9417310D0 (en) 1994-10-19
IS4401A (is) 1996-12-19
TR199501061A2 (tr) 1996-06-21
RU2159241C2 (ru) 2000-11-20
NO311297B1 (no) 2001-11-12
CA2198599C (en) 2000-06-06
DZ1923A1 (fr) 2002-02-17
IS1850B (is) 2003-02-07
FI970800A0 (fi) 1997-02-26
DE69501620T2 (de) 1998-07-02
GR3026475T3 (en) 1998-06-30
NZ288210A (en) 1998-01-26
RO116400B1 (ro) 2001-01-30
MA23650A1 (fr) 1996-04-01
DK0776323T3 (da) 1998-03-30
IL115013A0 (en) 1995-12-08
KR970705557A (ko) 1997-10-09
ATE163182T1 (de) 1998-02-15
SA95160156B1 (ar) 2005-05-30
MY113733A (en) 2002-05-31
ES2112650T3 (es) 1998-04-01
MX9701538A (es) 1997-05-31
EP0776323B1 (en) 1998-02-11
SK282922B6 (sk) 2003-01-09
SI9520091B (sl) 2004-10-31
LV11800A (lv) 1997-06-20
CA2198599A1 (en) 1996-03-07
ZA957142B (en) 1997-02-25
BG101250A (en) 1997-09-30
PL318319A1 (en) 1997-06-09
CO4410334A1 (es) 1997-01-09
LV11800B (en) 1997-10-20
HU227822B1 (en) 2012-03-28
HRP950460B1 (en) 2000-02-29
CZ287693B6 (en) 2001-01-17
UA45980C2 (uk) 2002-05-15
EP0776323A1 (en) 1997-06-04
SK24897A3 (en) 1998-08-05
EG23822A (en) 2007-09-19
AP9500754A0 (en) 1995-07-31
CZ56397A3 (cs) 1998-05-13
BR9503812A (pt) 1996-04-16
WO1996006842A1 (en) 1996-03-07
KR100228952B1 (ko) 1999-11-01
US6110940A (en) 2000-08-29
OA10600A (en) 2000-04-06
BG61840B1 (bg) 1998-07-31
NO970861L (no) 1997-02-26
CN1066727C (zh) 2001-06-06
YU49287B (sh) 2005-03-15
JP2904588B2 (ja) 1999-06-14
US6380226B1 (en) 2002-04-30

Similar Documents

Publication Publication Date Title
YU56995A (sh) Soli derivata indola
BR9911488A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou de profilaxia de doenças inflamatórias, e para a preparação de um composto
UA66750C2 (en) Substituted 1-phenylpirazole 3-carboxamides, a method for the preparation thereof and intermediary compounds, pharmaceutical composition having affinity to neurotensin receptors
EA199800290A1 (ru) (метилсульфонил) фенил-2-(5н)-фураноны в качестве ингибиторов циклооксигеназы-2
BR9714082A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto.
BR9911482A (pt) Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto
IL123002A0 (en) 1-Phenyl-2- phenylacetoxy- ethanone derivatives
EE03869B1 (et) Sulfiinhappe derivaadid, nende valmistamine ja kasutamine
ES2171723T3 (es) 3,4-diaril-2-hidroxi-2,5-dihidrofuranos como profarmacos de inhibidores de cox-2.
IL58782A0 (en) Hydroxypropyl-triazole compounds,their production and pharmaceutical compositions containing them
AU6319480A (en) 2-hydroxyalkyl-3,4,5-trihydroxypiperidines
IL78691A (en) Quinolylglycinamide derivatives,their preparation and pharmaceutical compositions containing them
AP9300561A0 (en) Antibiotic compounds.
AU623805B2 (en) New use of anti-progestomimetic compounds
EP1019047A4 (en) ANTITHROMBOTIC AGENTS
CA2107485A1 (fr) Nouveaux derives d'ellipticine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PL328225A1 (en) Diphenylstilbenes as pro-medications used to produce cox-2-inhibitors
YU37597A (sh) Novi derivati piranozida
FR2429201A1 (fr) Sulfoxydes utilisables comme agents initiateurs de photopolymerisation
BR9610175A (pt) Composto processo de preparação do composto composição farmacêutica e utilização do composto
EP1027051A4 (en) ANTITHROMBOTIC AGENTS
MA26734A1 (fr) Derives de 1-trifluoromethyl -4-hydroxy- 7-piperidinyl- aminomethylchromane, procede pour leur preparation et compositions pharmaceutiques les contenant
MX9303392A (es) Derivados de imidazo benzoxazin-1-ona substituidos y proceso para su preparacion.
BR9913601A (pt) Composto, uso do mesmo, composição farmacêutica, e, processo para a preparação de compostos
DE3372772D1 (en) Quinazolinone derivatives, process for their preparation and their use in medicaments